These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 37657881)
1. Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease. Sharma P; Sawtell R; Wang Q; Sise ME Adv Kidney Dis Health; 2023 Jul; 30(4):343-355. PubMed ID: 37657881 [TBL] [Abstract][Full Text] [Related]
2. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure]. Vallet-Pichard A; Pol S Nephrol Ther; 2015 Nov; 11(6):507-20. PubMed ID: 26423779 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus associated glomerulopathies. Ozkok A; Yildiz A World J Gastroenterol; 2014 Jun; 20(24):7544-54. PubMed ID: 24976695 [TBL] [Abstract][Full Text] [Related]
6. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update. Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019 [TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Rutledge SM; Chung RT; Sise ME Hemodial Int; 2018 Apr; 22 Suppl 1():S81-S96. PubMed ID: 29694729 [TBL] [Abstract][Full Text] [Related]
8. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789 [TBL] [Abstract][Full Text] [Related]
9. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Roth D; Bloom RD; Molnar MZ; Reese PP; Sawinski D; Sise ME; Terrault NA Am J Kidney Dis; 2020 May; 75(5):665-683. PubMed ID: 32279907 [TBL] [Abstract][Full Text] [Related]
10. Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. Strohbehn IA; Seethapathy R; Lee M; Sise ME Kidney360; 2021 Aug; 2(8):1316-1325. PubMed ID: 35369667 [TBL] [Abstract][Full Text] [Related]
11. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085 [TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. Mendizabal M; Reddy KR J Viral Hepat; 2017 Jun; 24(6):442-453. PubMed ID: 28107583 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Awan AA; Jadoul M; Martin P Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2158-2167. PubMed ID: 31376491 [TBL] [Abstract][Full Text] [Related]
17. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Lee JJ; Lin MY; Yang YH; Lu SN; Chen HC; Hwang SJ Am J Kidney Dis; 2010 Jul; 56(1):23-31. PubMed ID: 20400217 [TBL] [Abstract][Full Text] [Related]
18. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy. Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatitis C-related kidney disease. Fabrizi F; Martin P; Cacoub P; Messa P; Donato FM Expert Opin Pharmacother; 2015; 16(12):1815-27. PubMed ID: 26161511 [TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations". Pol S; Parlati L Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]